CUMBERLAND PHARMACEUTICALS INC (CPIX)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$11.0M
Cash & Equivalents
$0.4M
Quarterly Burn Rate
$88M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (4 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
CONIVAPTAN HYDROCHLORIDE
VAPRISOL |
APPROVED | Abscess, Acetaminophen Overdose, Acute Decompensated Heart Failure, Arthroscopic Knee Surgery, Aspirin Exacerbated Respiratory Disease (AERD), Asthma, Aspirin-Induced, Autism, Autoimmune Diseases, Bacteremia, Bacterial Pneumonia, Bowel Evacuant Prior to Colonoscopy, Burns, Cardiomyopathy, Dilated, Cardiovascular Diseases, Cellulitis, Chronic Heart Failure, Chronic Pelvic Pain, Colonoscopy, Colonoscopy Preparation, Complicated Skin and Skin Structure Infections, Connective Tissue Diseases, Constipation, Cystic Fibrosis, Duchenne Muscular Dystrophy Cardiomyopathy, Ductus Arteriosus, Patent, Dyslipidemias, End Stage Renal Disease, Euvolemia, Fever, GBM, Glioblastoma, Gram Positive Infection, Gram-Positive Bacterial Infections, Healthy, Hepatorenal Syndrome, Hospital Acquired Bacterial Pneumonia, Hypercholesterolemia, Hypervolemia, Hyponatremia, Idiopathic Pulmonary Fibrosis, Infections, Gram-Positive Bacterial, Kidney Diseases, Liver Cirrhosis, Liver Disease, Malignant Solid Tumor, Nephropathy, Obesity, Pain, Pa |
|
GRANISETRON
SANCUSO |
APPROVED | — |
|
TELAVANCIN HYDROCHLORIDE
VIBATIV |
NDA | — |
|
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE
OMECLAMOX-PAK |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.